Epitalon Half-Life & Pharmacokinetics — Research Guide (2026)

Research-use only. This guide summarises published pharmacokinetic (PK) data on Epitalon for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.

Epitalon is classified as a Synthetic tetrapeptide (Ala-Glu-Asp-Gly); pineal peptide bioregulator. Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.

At-a-Glance Pharmacokinetics

| Parameter | Epitalon | | --- | --- | | Classification | Synthetic tetrapeptide (Ala-Glu-Asp-Gly); pineal peptide bioregulator | | Serum half-life | Very short serum half-life of approximately 20–30 minutes in published preclinical PK reports — typical of small unmodified tetrapeptides. | | Tmax | Tmax of ~15–30 minutes following subcutaneous administration. | | Validated routes | Subcutaneous and intranasal routes are documented in published Russian and Eastern European research literature. | | Bioavailability | Moderate subcutaneous bioavailability; intranasal bioavailability lower but pharmacodynamically active in animal models. | | Clearance | Rapid enzymatic hydrolysis to constituent amino acids; no accumulation observed in multi-dose protocols. |

Serum Half-Life

Very short serum half-life of approximately 20–30 minutes in published preclinical PK reports — typical of small unmodified tetrapeptides.

Tissue vs Serum

Functional pharmacodynamic duration (telomerase activity, melatonin axis modulation) extends well beyond serum clearance in cellular and animal studies.

The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For Epitalon, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.

Time to Peak (Tmax)

Tmax of ~15–30 minutes following subcutaneous administration.

Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.

Routes of Administration

Subcutaneous and intranasal routes are documented in published Russian and Eastern European research literature.

Bioavailability across routes: Moderate subcutaneous bioavailability; intranasal bioavailability lower but pharmacodynamically active in animal models.

Clearance & Metabolism

Rapid enzymatic hydrolysis to constituent amino acids; no accumulation observed in multi-dose protocols.

Key Pharmacokinetic Takeaways

• Tetrapeptide with serum PK dominated by rapid enzymatic hydrolysis
• Short-course pulse protocols (10–20 day cycles) are characteristic of the published literature
• Functional duration of effect is decoupled from serum exposure
• Pharmacokinetic profile justifies cycled rather than continuous research dosing

Frequently Asked Questions

What is the half-life of Epitalon? Very short serum half-life of approximately 20–30 minutes in published preclinical PK reports — typical of small unmodified tetrapeptides.

How quickly does Epitalon reach peak concentration? Tmax of ~15–30 minutes following subcutaneous administration.

Which routes of administration are validated in published research? Subcutaneous and intranasal routes are documented in published Russian and Eastern European research literature.

Does Epitalon accumulate with repeat dosing? Rapid enzymatic hydrolysis to constituent amino acids; no accumulation observed in multi-dose protocols. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.

Is oral bioavailability meaningful for Epitalon? Moderate subcutaneous bioavailability; intranasal bioavailability lower but pharmacodynamically active in animal models.

Related Research

• Reconstitution & storage protocols — see the Epitalon reconstitution guide for vial handling that preserves the PK profile described above.
• Dosing protocols research — see the Epitalon dosing protocols article for how PK parameters translate into scheduling decisions.
• Mechanism of action — see the Epitalon mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.

---

*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*